NCT03079440View on ClinicalTrials.gov

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

November 15, 2020

Study Completion Date

November 15, 2022

Conditions
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomideCapecitabine
Interventions
DRUG

TEMCAP

Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14

Trial Locations (1)

05505

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter